Subperiosteal chin augmentation with hyaluronic acid filler in patients with a small chin

Kyoungjin Kang, MD, PhD, FKCCS¹, Choongyee Chai, MS²

¹Seoul Cosmetic Surgery Clinic, Busan, Rep. of Korea, ²Korean College of Cosmetic Surgery, Busan, Rep. of Korea

Introduction

Patients with a small chin have typical features, such as a wide and short face, protruded mouth, chin drooping, exposed teeth due to incomplete lip closure, bunching and pouting, and wrinkles and dimpling of the skin [1]. In addition, many patients may experience dryness of the mouth because of incomplete mouth closure during sleep.

Sliding genioplasty, autologous or allograft implantation, and filler injection have been performed as representative treatment modalities for the small chin [2]. Among these, the filler procedure is commonly used for chin augmentation because of...
the minimal downtime and fewer complications. Moreover, the recent trend of non-invasive cosmetic surgery, rather than the perfection and persistence of the procedure’s treatment effects, may have contributed to its popularity.

Usually, fillers are injected into the intradermal, subdermal, and supraperiosteal layers to correct small chins [3] and both sharp needles and blunt cannulas were inserted at three points of the entry site [4]. Apart from common complications, such as swelling, redness, tenderness, bruising, filler migration, bumps or lumps, asymmetry, irregularities, and nodules, relatively serious complications, such as chin drooping have also occurred frequently [5]. Among these, the mechanism of chin drooping is as follows: when the filler is injected into the intradermal, subdermal, and supraperiosteal layer in a patient who has a small and flat chin, chin drooping can occur more easily because of decreased skeletal support for the chin soft tissue. This is caused by increased soft tissue weight from the injected filler.

This hypothesis is supported by some studies that reported that facial sagging was caused not only by soft tissue aging, but also by skeletal deformities [6,7], and that it can be improved by the modification of volume restoration from the bone and soft tissues [8]. Thus, a small chin can easily lead to incomplete mouth closure and teeth exposure when the mentalis muscle is relaxed. Therefore, most patients with a small chin tend to excessively contract the mentalis muscle to close their mouth. This is the main cause of bunching, pouting, and soft tissue deformities, such as chin wrinkles, mentalis dimpling [9], and loss of the submental fat pad. Further, the opening of the mouth during sleep due to mentalis relaxation can lead to drying of the mouth.

Finally, the authors suggest that subperiosteal filler injection is the fundamental solution to the above complications. It is expected to produce not only chin augmentation, but also decrease the gap between the lips by increasing skeletal support. Additionally, the authors used a sharp needle and six to eight points of entry for the exact and even placement of the filler. Botulinum toxin treatment was also administered to prevent filler migration postoperatively.

To evaluate the effect of the subperiosteal filler augmentation, the change in the lower one-third of the facial proportion, modified Legan’s angle, gap between the lips, and the morphological changes of the chin, lips, and perioral area were evaluated from the pre- and postoperative photographs of the patients.

Materials and methods

Patients and follow-up

Filler chin augmentation was performed for 14 patients with a small chin who visited the Seoul Cosmetic Surgery Clinic between March and June 2017. The effect of the augmentation was assessed 2–3 weeks after the procedure.

Preoperative marking

Three vertical lines (a, b and c) were first marked, two horizontal lines (e and f) were made separately after touching the Superior and inferior borders of the mandible with the fingertips. The intersections of the three vertical and two horizontal lines were used as the entry points (i.e., 1, 2, 3, 4, 5 and 6). Subsequently, the naturally expanded semi-circular lateral areas were located while pinching the soft tissue of the medial commissure with the thumb and index finger. A black-colored outline, like a school bus track, was made for the chin augmentation. The labiomental depression was marked and its entry

Fig. 1. Preoperative markings for sequential augmentation of filler injection (SAFI). (A) Schematic drawing for determination of injection area and entry site, (B) Practical marking for filler injection in the state of the mentalis muscle in repose. The numbers (i.e., 1 to 8) represent the entry sites. Upper/lower white dotted lines indicate surface marking lines from superior/inferior border of mandible respectively. (a) and (c) Two vertical black-colored dotted lines indicate the boundary line between the medial and lateral part of the vermilion, (b) A vertical black-colored dotted line indicates the center of medial part of the vermilion, (d) A black-colored dotted line indicates lower vermilion border, and (e) Transverse line on the skin corresponds to muco-buccal fold in oral cavity, and (f) Transverse line for inferior border of mandible. Upper and lower blue arrows indicate the direction of needle insertion and bevel’s orientation.
points were numbers 7 and 8 (Fig. 1).

**Anesthesia**

0.1 ml of 2% lidocaine solution mixed with epinephrine (1:100,000) was injected into the eight entry sites from the periosteum to the skin, retrogradely.

**Filler and botulinum toxin injection**

In the first session of the filler injection, an average of 2.43±0.73 ml of Elravie® Premier Ultravolume-L (hyaluronic acid 23mg/ml, 0.3% lidocaine, Humedix Co., Ltd., Anyang, Republic of Korea) were injected. Where needed, a second session was performed at least 2–3 weeks later. Subperiosteal bolus injection of the filler was performed through the entry sites in the order of 1 to 6. Thereafter, the filler was injected into the labiomental depression through the other entry sites (7 and 8) (Fig. 1A). A 23 gauge sharp needle was inserted into the 2-cc syringe of the filler. The needle was approached towards the central zone of the medial commissure of the lower lip, touching the bone directly, and the filler was slowly injected after checking intravascular injection by withdrawing the plunger. At any entry site, the bevel of the needle can be oriented upwards, downwards or laterally according to the purpose of the injection (projection, lengthening, or widening of the chin). Medytoxin® (10 units/0.5 cc of Botulinum toxin; Meditox Inc., Cheongju, Republic of Korea) was injected into the mentalis muscle to prevent postoperative migration of the filler. A 3M tape was used to fix the chin for 3 days postoperatively, and cold compression was applied for 2 days.

**Measurement**

**Proportion of the lower one-third of the face**

Changes in the length of each zone (I, II, and III) were measured from the pre- and postoperative photographs and the change of the pre- and postoperative ratio was also calculated (Fig. 2A).

**Modified Legan’s angle**

To evaluate the anterior projection of the soft tissues, we measured the modified Legan’s angle [10], which is the angle between the line from the nasion to the subnasale and the line from the pogonion to the subnasale (Fig. 2B).

**The gap between the lips**

The gap between the upper and lower lips when the mentalis muscle is relaxed was measured before and after the procedure using a ruler (Fig. 2C).

**Morphological changes of the chin, lips, and perioral area**

From the pre- and postoperative photographs, contour changes of the chin, lips, nasolabial folds, and perioral wrinkles, when the corner of the mouth is elevated, were also observed.

**Dry mouth**

Two to three weeks after the procedure, patients who had subjective symptoms such as dryness of the mouth prior to the procedure were examined to ascertain whether the symptom had improved. We assumed the perception of the symptom

---

**Fig. 2.** Measurements of lower face proportion, modified Legan’s angle and open gap between upper and lower lips. (A) Frontal view of facial proportion, (B) Lateral view of Legan’s angle, (C) Frontal view of measurement of gap distance in the status of mentalis muscle in repose. Zone I, II, and III represent the upper, middle and lower 1/3 of the lower face, Sn, subnasale; St, stomion; Lm, labiomental crease; Mt, menton; N, nasion; P, pogonion; L, Legan’s angle.
before the procedure to be 100%; thus, the perception of the symptom after the procedure was recorded as percentages.

Results

Statistical analysis

Amount of Botulinum toxin and hyaluronic acid filler used
Ten units of Medytoxin® and Elravie® (mean, 2.43±0.73 ml) Premier Ultravolume-L were injected. For chin projection, more amount of filler was injected into 1, 2, and 3 entry sites than into 4, 5, 6 entry sites (Table 1).

Proportion of the lower one-third of the face
The total length of the lower face was increased (p=0.003). Among the zones, only the increase in the length of zone III was statistically significant (p<0.05). The ratio of the length of each zone to the total length of the lower face showed significant changes in zone I and III (p=0.001 and p=0.000, respectively). However, there was no statistically significant change in zone II (Table 2, 3).

Modified Legan's angle
As shown in the photograph, the decrease in Legan’s angle indicated an increase in the anterior projection of the soft tissues of the small chin. As seen in the figures, this angle was significantly reduced in all patients, after the procedure, by an average of 37.1±16.71% (Table 4).

The gap between the lips
The gap between the lips significantly reduced in all cases, after the procedure (Table 4). In this study, the rate of decrease in the gap between the lips after the procedure was 66.2±17.89%.

Dry mouth
Preoperatively, eight of the patients had subjective symptom of dry mouth when they woke up in the morning. Among them, one patient had no improvement (0%) after the procedure, however, the seven other patients experienced a significant decrease in the symptom (77.14±20.59%) (Table 4).

Complications
Swelling and pressure pain occurred in all cases but disappeared within one week. Bleeding and bruising at the entry sites of the lidocaine injection occurred in two patients. Moreover, asymmetry occurred, which was not caused by over-correction or hypo-correction but was caused by the difference in soft tissue thickness, which had been reduced by excessive mentalis muscle contraction before the procedure. The subjective opinions of patients ‘my chin became too big after the procedure’

Table 1. Amount of Hyaluronic acid filler and botulinum toxin used for chin and prejowl area

| Number of cases (n) | Sex | Age | Medytoxin* (units) | Total amount (ml) | Elravie® premier ultravolume-L hyaluronic acid fillerb | Injected amount to each entry site (ml) | Injected amount to prejowl | Right | Left |
|---------------------|-----|-----|-------------------|------------------|---------------------------------|--------------------------------------|-----------------------------|-------|------|
| 1                   | F   | 60  | 10                | 2.1              | Medytoxin® 2                         | 0.2                                  | 0.4                          | 0.2   | 0.4  |
| 2                   | F   | 33  | 10                | 2.5              | Elravie® 0.3                         | 0.1                                  | 0.6                          | 0.3   | 0.1  |
| 3                   | M   | 40  | 10                | 2                | Premier Ultravolume-L 0.4            | 0.2                                  | 0.4                          | 0.2   | 0.4  |
| 4                   | F   | 34  | 10                | 2                | Medytoxin® 0.4                       | 0.3                                  | 0.3                          | 0.1   | 0.4  |
| 5                   | F   | 61  | 10                | 2                | Elravie® 0.4                         | 0.3                                  | 0.4                          | 0.1   | 0.4  |
| 6                   | F   | 48  | 10                | 2                | Premier Ultravolume-L 0.5            | 0.2                                  | 0.3                          | 0.3   | 0.3  |
| 7                   | F   | 61  | 10                | 2.25             | Medytoxin® 0.4                       | 0.4                                  | 0.4                          | 0.2   | 0.3  |
| 8                   | F   | 64  | 10                | 1.2              | Premier Ultravolume-L 0.4            | 0.2                                  | 0.3                          | 0.2   | 0.2  |
| 9                   | F   | 44  | 10                | 4                | Medytoxin® 0.6                       | 0.6                                  | 0.6                          | 0.4   | 0.4  |
| 10                  | F   | 52  | 10                | 3.2              | Premier Ultravolume-L 0.5            | 0.3                                  | 0.7                          | 0.5   | 0.5  |
| 11                  | F   | 61  | 10                | 3                | Medytoxin® 0.4                       | 0.4                                  | 0.4                          | 0.2   | 0.4  |
| 12                  | F   | 60  | 10                | 2                | Premier Ultravolume-L 0.3            | 0.3                                  | 0.3                          | 0.2   | 0.5  |
| 13                  | F   | 48  | 10                | 3.4              | Medytoxin® 0.6                       | 0.2                                  | 0.6                          | 0.5   | 0.2  |
| 14                  | F   | 63  | 10                | 2.3              | Premier Ultravolume-L 0.4            | 0.2                                  | 0.4                          | 0.2   | 0.4  |
| AVG                 | 52.07| 10  | 2.43              | 0.41             | 0.26                               | 0.45                                 | 0.39                         | 0.21  | 0.40 |
| SD                  | 10.96| 0    | 0.73              | 0.10             | 0.12                               | 0.12                                 | 0.12                         | 0.13  | 0.09 |

*Botulinum toxin, **Hyaluronic acid filler, AVG, average; SD, standard deviation.
were noted as overcorrection. Apart from this, there are no significant complications which have been reported by other researchers (Table 5).

**Morphological analysis**

**Shape of chin**

The chin was projected anteriorly and lengthened inferiorly and the labiamental crease moved superiorly due to increased skeletal support by the subperiosteal augmentation. Lengthening of the lower one-third of the face by chin augmentation significantly contributed to the change in the facial contour from round to elliptical (Fig. 3). Mental dimpling was immediately improved, although the filler was injected into the subperiosteal layer, and it was corrected with the combination of the botulinum toxin treatment (Fig. 4A, B).

**Shape of the mouth and lips**

Despite the eversion of the upper lip and shortening of the philtrum, the mouth looked small and less protruded (Fig. 3A, B). The lower lip was inverted and volumized, projected anteriorly, and rotated counterclockwise (Fig. 4C, D). These were due to the increased skeletal support by the chin augmentation.

The preoperative sagging appearance of the upper lip was improved by the shortened distance between the subnasale and the vermilion border of the upper lip. It was because of the need, to close mouth due to the decreased gap distance, was reduced (Fig. 3, 4).

**Change of perioral animation**

Before the procedure, the corner of the mouth was superolateral and perioral wrinkles, chin wrinkles, labiandomandibular folds,
and the mental dimple were obvious when the corner of the mouth was elevated strongly (Fig. 5A, C) due to the combined contraction of the mentalis and risorius muscles. However, after the chin augmentation, the wrinkles and the folds were noticeably softened and shortened. The mental dimple was also corrected (Fig. 5B, D). This effect was caused the hypo-contraction of mentalis muscle, which was induced by subperiosteal filler augmentation.

**Discussion**

The injectable filler has been very popularly used to improve the lower facial contour with the correction of a small chin [4]. Although filler augmentation has been considered as an easy procedure, complications such as nodules, bumps, lumps, filler migration, asymmetry, and chin ptosis have frequently occurred when the filler is injected into the subdermal, intramuscular, and submuscular layers, as shown in Fig. 6. Moreover, the incidence of complication is known to depend on the type, placement, and amount of the injected filler and the skill of the physician who performs the procedure. Because of this, the authors obtained some notable results by injecting the filler into the subperiosteal layer, which has not been commonly used for chin augmentation.

After subperiosteal augmentation, the small chin and contour of the lower face were notably improved. Bunching and pouting with a mental dimple, perioral wrinkles, and labio-mandibular folds immediately disappeared (Fig. 3). The gap between the lips was considerably decreased in all cases and almost all of the patients had great satisfaction with the easy closing of the mouth, and some patients had significant improvement of the early morning dry mouth (Table 4). Moreover, common complications were almost prevented or showed a very low incidence (Table 5).

| Table 4. Change of modified Legan’s angle, open gap distance between lips, and change of dry mouth |
|---------------------------------------------------------------|
| **Number Of cases (n)** | **Sex** | **Age** | **Modified Legan’s angle(*)** | **Open gap distance (mm)** | **Change of dry mouth as a subjective symptom (%)** |
|------------------------|--------|--------|-----------------------------|--------------------------|-----------------------------------------------|
|                        |        |        | Before | After | RR (%) | Before | After | RR (%) | Before | After | RR (%) |
| 1                      | F      | 60     | 8      | 3     | 62.5    | 7.5    | 2.5   | 66.7    | 100    | 20    | 80     |
| 2                      | F      | 33     | 13     | 9.5   | 26.9    | 6      | 2     | 66.7    | 0      | 0     | -      |
| 3                      | M      | 40     | 11     | 8     | 27.3    | 2      | 0.5   | 75      | 0      | 0     | -      |
| 4                      | F      | 34     | 24.5   | 19.5  | 20.4    | 2      | 0.5   | 75      | 0      | 0     | -      |
| 5                      | F      | 61     | 6      | 2     | 66.7    | 2      | 0     | 100     | 100    | 50    | 50     |
| 6                      | F      | 48     | 11.3   | 7.8   | 31      | 7      | 3     | 57.1    | 100    | 20    | 80     |
| 7                      | F      | 61     | 21.7   | 16.2  | 25.3    | 3      | 0     | 100     | 0      | 0     | -      |
| 8                      | F      | 64     | 6      | 3.5   | 41.7    | 5      | 2     | 60      | 100    | 0     | 100    |
| 9                      | F      | 44     | 24     | 19    | 20.8    | 7      | 4     | 42.9    | 0      | 0     | -      |
| 10                     | F      | 52     | 15.5   | 8.5   | 45.2    | 7      | 2.5   | 64.3    | 100    | 50    | 50     |
| 11                     | F      | 61     | 13     | 8     | 38.5    | 8      | 4.5   | 43.8    | 100    | 100   | -      |
| 12                     | F      | 60     | 14.5   | 11    | 24.1    | 9      | 5     | 44.4    | 0      | 0     | -      |
| 13                     | F      | 48     | 21     | 16    | 23.8    | 5      | 2     | 60      | 100    | 20    | 80     |
| 14                     | F      | 63     | 6.5    | 2.3   | 64.6    | 7      | 2     | 71.4    | 100    | 0     | 100    |
| **AVG**                | F      | 52.1   | 14     | 9.59  | 37.1    | 5.54   | 2.18  | 66.2    | 77.14  | -     | -      |
| **SD**                 |        | 5.61   | 14     | 9.59  | 37.1    | 5.54   | 2.18  | 66.2    | 77.14  | -     | -      |

*(a)The change of subject symptom of dry mouth after the procedure if considering that dry mouth symptom felt before the procedure is 100%; *(b)RR: Reduction ratio (%)=(After×100/Before)–100; *(c)AVG, average; *(d)SD, standard deviation.

| Table 5. Possible complications and incidence from filler augmentation |
|---------------------------------------------------------------|
| **Complications** | **Incidence (%)** | **Complications** | **Incidence (%)** |
|-------------------|-------------------|-------------------|-------------------|
| Swelling/Pressure Pain | 14/14 (100) | Lumps/ Bumps | 0/14 (0) |
| Bleeding/Bruising | 2/14 (14) | Infection /Inflammation | 0/14 (0) |
| Asymmetry due to uneven surface | 2/14 (14) | Nodules | 0/14 (0) |
| Overcorrection | 2/14 (14) | Vascular occlusion | 0/14 (0) |
| Migration | 0/14 (0) | Chin drooping | 0/14 (0) |

*(a)Incidence (%), Number of patients who have complications/Total number of patients×100.
Moreover, these morphological effects were strongly supported by the statistical analysis, which is as follows: the length of the lower one-third from the lower border of the face was increased and its proportional ratio to the lower face was also increased. It supported the change of contour in the lower face from round with a sagging appearance to elliptical with a lifted appearance (Table 3). The modified Legan’s angle was significantly decreased in all cases. It strongly supported the anterior projection of the small chin, and eventually, the mouth looked smaller and less protruding. The decreased gap between the lips was due to increased skeletal support by the chin augmentation (Table 4). The augmentation resolved the mental dimple with bunching and pouting and prevented perioral animation (Fig. 4, 5). From these results, it was confirmed that there was a close correlation between the statistical measurements and the morphological analysis.

The morphological change in the length of the middle one-third was not obvious and there was also no statistically significant change in the length of the middle one-third. This was due to the inversion and anterior projection of the lower lip and also due to the influence of the decrease in the length of the upper lip caused by the decrease in the gap between the lips (Fig. 3, 4).

The reason for the decrease of the upper one-third was because the gap between the lips was markedly reduced by the change of the lower and middle one-third, and the need to contract the orbicular oris muscle in order to close the mouth was reduced.

The authors would like to describe the mechanism as below. First, we need to understand the basic concepts of the size and shape of the facial bones and the skeletal support of the soft tissues surrounding them. In other words, small and flat bones provide poor skeletal support to the surrounding soft tissues,
resulting in the sagging of the soft tissues, while large and pro-
truded bones provide strong skeletal support to the surrounding
soft tissues, preventing sagging [11]. Therefore, the soft tissues
on the small and flat bony mentum receive poor skeletal sup-
port, and in terms of the mentalis muscle in relaxation, the soft
tissues of the chin, including the lower lip, sagged and eventu-
ally resulted in incomplete mouth closure. In order to avoid this,
patients usually will contract the mentalis muscle to close their
mouths and it is at this time that the mouth appears to protrude
as bunching and pouting with the appearance of the mentalis
dimple. In this kind of situation, if the filler is injected into the
subdermal, intramuscular, submuscular, and supraperiosteal
layers, it induces poor skeletal support and not only increases
chin ptosis but also causes the injected filler to migrate from the
injection site, gathering into bumps, lumps, or nodules beneath
the skin because of bunching and pouting due to continuous
mentalis contraction [12].

In this study, there were no complications such as chin ptosis
and vascular occlusion as shown in Table 5. We used six entry
sites and attempted to correct the asymmetric chin by inject-
ing different amounts of the filler into each site. However, in the
area of mental dimpling where the amount of soft tissue signifi-
cantly decreased before the procedure, an uneven surface oc-
curred in two cases and it was the main cause of the asymmetry.
This was corrected by injecting a small amount of filler into the
subdermal and submuscular layers.

The purpose of this study was not to increase the volume of
the soft tissues of the chin but to correct the bony deformity of
the small and flat mentum through subperiosteal injection and
eventually increase the skeletal support provided to the soft tis-
sues. Marked improvements were noted as mentioned above
and additionally, the incidence of complications was decreased.
Subperiosteal filler injection is a noteworthy alternative for the correction of the small chin without chin ptosis. Moreover, its additional benefits, such as the improvement of dry mouth, lips contour, and perioral wrinkles are attributed to the increased skeletal support for the soft tissues of the lower lip and chin by the subperiosteal placement of the filler.

Fig. 5. Immediate change of perioral animation after filler injection. Filler was injected into a 52-year-old woman who had a small chin (9th case from Table 1 and 2). (A) and (C) Before procedure, (B) and (D) Immediately after procedure.

Fig. 6. A complication case characterized by tiny multiple nodules, mental dimples, asymmetry, and chin ptosis occurred to the patient, who has been injected man-made filler into intradermal, subcutaneous, and submuscular layers. (A) Frontal view, (B) Lateral view.

Conclusion

Subperiosteal filler injection is a noteworthy alternative for the correction of the small chin without chin ptosis. Moreover, its additional benefits, such as the improvement of dry mouth, lips contour, and perioral wrinkles are attributed to the increased skeletal support for the soft tissues of the lower lip and chin by the subperiosteal placement of the filler.

Acknowledgments

Our sincere gratitude goes to Park Min-Su, Ph.D. who contributed to the quality improvement of this paper with appropriate and excellent statistical analysis.

Conflicts of interest

The authors have nothing to disclose.
References

1. Kang KJ. SAFI (Sequential autologous fat injection). Seoul: Koonja Publishing Inc.; 2017. p. 234-36.
2. Bertossi D, Galzignato PF, Albanese M, Botti C, Botti G, Nocini PF. Chin microgenia: a clinical comparative study. Aesthetic Plast Surg 2015;39:651-8.
3. Bass LS. Injectable filler techniques for facial rejuvenation, volumization, and augmentation. Facial Plast Surg Clin North Am 2015;23:479-88.
4. Rho NK, Chang YY, Chao YY, Furuyama N, Huang PY, Kersther M, et al. Consensus recommendations for optimal augmentation of the Asian face with hyaluronic acid and calcium hydroxylapatite fillers. Plast Reconstr Surg 2015;136:940-56.
5. Garfein ES, Zide BM. Chin ptosis: classification, anatomy, and correction. Craniomaxillofac Trauma Reconstr 2008;1:1-14.
6. Mendelson B, Wong CH. Changes in the facial skeleton with aging: implications and clinical applications in facial rejuvenation. Aesthetic Plast Surg 2012;36:753-60.
7. Rohrich RJ, Pessa JE. Discussion. Aging of the facial skeleton: aesthetic implications and rejuvenation strategies. Plast Reconstr Surg 2011;127:384-5.
8. Shaw RB Jr, Katznel EB, Koltz PF, Yaremchuk MJ, Girottja JA, Kahn DM, et al. Aging of the facial skeleton: aesthetic implications and rejuvenation strategies. Plast Reconstr Surg 2011;127:374-83.
9. Carruthers J, Fagien S, Matarasso S; Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg 2004;114(6 Suppl):1S-22S.
10. Arroyo HH, Olivetti IP, Lima LF, Jurado JR. Clinical evaluation for chin augmentation: literature review and algorithm proposal. Braz J Otorhinolaryngol 2016;82:596-601.
11. Kang KJ. SAFI (Sequential autologous fat injection). Seoul: Koonja Publishing Inc.; 2017. p. 71-6.
12. Belmontesi M, Grover R, Verpaele A. Transdermal injection of Restylane SubQ for aesthetic contouring of the cheeks, chin, and mandible. Aesthet Surg J 2006;26(1S):S28-34.